Genta, Jagotec AG deal

Based on pilot human pharmacokinetic studies, the companies' Genta Jago joint venture will begin manufacturing scale-up of a potentially bioequivalent formulation of Procardia XL (extended-release nifedipine), a calcium channel blocker marketed by Pfizer Inc. and manufactured by ALZA Corp. (AZA).

The joint venture announced last year that an early Geomatrix formulation was not bioequivalent to the reference product. ...